Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy.
| Title: | Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy. |
|---|---|
| Authors: | Jordão ML; Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.; Hatanaka M; University of São Paulo School of Medicine, São Paulo, Brazil.; Ogundele A; Global Medical Affairs, Alcon Laboratories, Inc., Fort Worth, TX, USA.; de Moraes Silva MR; Faculty of Medicine of Botucatu, Universidade Estadual Paulista (UNESP), São Paulo, Brazil.; Vessani RM; General Hospital of Itapecerica da Serra, Serviço Social da Construção Civil do Estado de São Paulo (SECONCI-SP) São Paulo, Brazil. |
| Source: | Clinical ophthalmology (Auckland, N.Z.) [Clin Ophthalmol] 2014 Aug 18; Vol. 8, pp. 1527-34. Date of Electronic Publication: 2014 Aug 18 (Print Publication: 2014). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101321512 Publication Model: eCollection Cited Medium: Print ISSN: 1177-5467 (Print) Linking ISSN: 11775467 NLM ISO Abbreviation: Clin Ophthalmol Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Auckland : Dove Medical Press, c2007- |
| Abstract: | Objective: To assess the intraocular pressure (IOP)-lowering effect of travoprost 0.004%/timolol 0.5% fixed-dose combination (TRAV/TIM-FC) in patients not achieving the target IOP of ≤18 mmHg while on timolol 0.5% (TIM) monotherapy.; Methods: A multicenter, prospective, open-label study (NCT01336569) was conducted in patients with open-angle glaucoma or ocular hypertension. Eligible patients were receiving TIM monotherapy with a screening/baseline IOP of 19-35 mmHg in ≥1 eye. TIM was discontinued on the baseline visit day (no washout period) and TRAV/TIM-FC was initiated and administered once daily at 8 pm for 4-6 weeks. The primary efficacy variable was mean change in IOP from TIM-treated baseline to study end, measured by Goldmann applanation tonometry. Results were analyzed by analysis of variance and paired samples t-test (5% significance).; Results: A total of 49 patients were enrolled (mean age, 63 [range, 42-82] years; 55.1% White; 73.5% women), and 45 were included in the intent-to-treat (ITT) population. Mean duration of treatment with TRAV/TIM-FC was 31 days. Mean ± standard deviation IOP reduction from baseline (TIM) to the follow-up visit (TRAV/TIM-FC) was -5.0±3.6 mmHg. IOP decreased significantly (P |
| References: | J Ocul Pharmacol Ther. 2013 May;29(4):382-9. (PMID: 23231442); Clin Ophthalmol. 2012;6:699-706. (PMID: 22654495); J Pharm Sci. 1974 Mar;63(3):333-8. (PMID: 4820359); Eye (Lond). 2011 Sep;25(9):1161-9. (PMID: 21701528); Am J Ophthalmol. 2007 Oct;144(4):533-40. (PMID: 17686450); Am J Ophthalmol. 2000 Oct;130(4):429-40. (PMID: 11024415); Ann Pharmacother. 2002 Mar;36(3):504-11. (PMID: 11895065); Clin Ophthalmol. 2008 Jun;2(2):313-9. (PMID: 19668722); Value Health. 1998 Sep;1(3):171-3. (PMID: 16674348); Clin Ophthalmol. 2010 May 14;4:459-66. (PMID: 20505839); Clin Ophthalmol. 2010 Feb 02;4:1-9. (PMID: 20169043); Acta Ophthalmol. 2012 Feb;90(1):20-31. (PMID: 22289192); Am J Ophthalmol. 2005 Jul;140(1):1-7. (PMID: 15990081); Ophthalmology. 2006 Mar;113(3):431-6. (PMID: 16458967); J Ocul Pharmacol Ther. 2008 Aug;24(4):414-20. (PMID: 18665813); J Glaucoma. 2009 Mar;18(3):238-43. (PMID: 19295380); Ophthalmology. 2005 Jun;112(6):953-61. (PMID: 15885795); J Med Assoc Thai. 2011 Mar;94 Suppl 2:S81-7. (PMID: 21717884); Am J Ophthalmol. 2005 Aug;140(2):242-50. (PMID: 16086946); Ophthalmology. 1998 Oct;105(10):1945-51. (PMID: 9787368); Acta Clin Croat. 2010 Dec;49(4):411-9. (PMID: 21830452); J Glaucoma. 2003 Oct;12(5):393-8. (PMID: 14520147); Br J Ophthalmol. 2006 Mar;90(3):262-7. (PMID: 16488940); Drugs Aging. 2008;25(9):729-59. (PMID: 18729546); Eur J Ophthalmol. 2007 Mar-Apr;17(2):183-90. (PMID: 17415690); Expert Opin Pharmacother. 2012 Apr;13(5):757-66. (PMID: 22360540); Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30. (PMID: 12049574); Br J Ophthalmol. 2002 Apr;86(4):418-23. (PMID: 11914211); Br J Ophthalmol. 2009 Apr;93(4):481-5. (PMID: 19019932) |
| Contributed Indexing: | Keywords: DuoTrav®; intraocular pressure; primary open-angle glaucoma; time since diagnosis |
| Entry Date(s): | Date Created: 20140830 Date Completed: 20140829 Latest Revision: 20211021 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC4144930 |
| DOI: | 10.2147/OPTH.S66613 |
| PMID: | 25170245 |
| Database: | MEDLINE |
Journal Article